AVA-291 is a novel testosterone formulation for women, designed to resist aromatization and reduce breast cancer risk. Data shows AVA-291 has a 1,000-fold lower potential to stimulate breast cancer ...
Pedro F.S. Freitas, MD, recaps his talk at the 2026 Desai Sethi Urology Institute Urology on the Beach meeting. In an interview at the 2026 Desai Sethi Urology Institute Urology on the Beach meeting, ...
PANVAC addition to BCG therapy did not improve recurrence-free survival in high-grade NMIBC patients compared to BCG alone. No significant differences were observed in secondary endpoints, including ...
Rahul Aggarwal, MD, shares key takeaways from the PRESTO trial as well as remaining questions in the field. The phase 3 PRESTO trial (NCT03009981) assessed combined androgen signaling blockade for a ...
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial. On November 21, 2025, the FDA approved pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph ...
At the 2025 LUGPA Annual Meeting, Jonathan Henderson, MD, delivered a talk titled, “Lessons Learned: Avoiding Pitfalls in Urology Practice Management.” During the meeting, Henderson sat down with ...
Non-muscle invasive bladder cancer treatments have expanded beyond BCG, offering alternatives to radical cystectomy with flexible dosing and scheduling. Muscle-invasive bladder cancer management is ...
"As urologists, we should be proactive and creative as we find new ways to attract, retain and train the next generation," writes Michael S. Cookson, MD, MMHC, FACS. The 2025 RAND-AAMC system-dynamics ...
Neal Shore, MD; Sam Chang, MD, MBA; Max Kates, MD; and Katie Murray, DO, MS, discuss how the recent FDA approval of UGN-102 (mitomycin gel) provides a paradigm-shifting ablative treatment option for ...
Enzalutamide plus ADT significantly reduced the risk of radiographic progression or death and castration resistance compared to darolutamide plus ADT in mHSPC patients. The MAIC analysis provided a ...
A 500 mg dose of abiraterone acetate showed comparable efficacy to the standard 1000 mg dose in prostate cancer treatment, with a favorable safety profile. The study demonstrated significant PSA ...
Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, antibiotic use, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results